Get the Stockscreener App
17.57
2.33%
-0.42
Summit Therapeutics Inc stock is traded at $17.57, with a volume of 1.59M.
It is down -2.33% in the last 24 hours and down -6.69% over the past month.
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
See More
Previous Close:
$17.99
Open:
$17.97
24h Volume:
1.59M
Relative Volume:
0.47
Market Cap:
$13.08B
Revenue:
$220.00K
Net Income/Loss:
$-746.08M
P/E Ratio:
-17.44
EPS:
-1.0074
Net Cash Flow:
$-211.81M
1W Performance:
-4.04%
1M Performance:
-6.69%
6M Performance:
-12.85%
1Y Performance:
-1.68%
1-Day Range:
$17.39
$18.02
1-Week Range:
$16.81
$18.74
52-Week Range:
$15.55
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
Name
Summit Therapeutics Inc
Sector
Industry
Phone
305-203-2034
Address
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
17.57 | 13.39B | 220.00K | -746.08M | -211.81M | -1.0074 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Sep-17-25 | Initiated | Barclays | Underweight |
| Sep-04-25 | Initiated | Guggenheim | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Neutral |
| Jul-01-25 | Initiated | UBS | Buy |
| Jun-11-25 | Initiated | Leerink Partners | Underperform |
| Mar-26-25 | Upgrade | Citigroup | Neutral → Buy |
| Mar-21-25 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-12-25 | Initiated | Evercore ISI | Outperform |
| Feb-28-25 | Initiated | Goldman | Buy |
| Jan-08-25 | Initiated | Truist | Buy |
| Dec-11-24 | Initiated | Wells Fargo | Overweight |
| Dec-06-24 | Initiated | Jefferies | Buy |
| Nov-04-24 | Initiated | JMP Securities | Mkt Outperform |
| Sep-27-24 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-24 | Initiated | H.C. Wainwright | Buy |
| May-07-24 | Initiated | Citigroup | Buy |
| Mar-26-24 | Initiated | Stifel | Buy |
| Jun-28-18 | Downgrade | Janney | Buy → Neutral |
| May-02-18 | Initiated | Janney | Buy |
| Apr-12-18 | Reiterated | Needham | Buy |
| Feb-13-18 | Initiated | BTIG Research | Buy |
| Jan-04-18 | Initiated | SunTrust | Buy |
| Dec-01-17 | Resumed | H.C. Wainwright | Buy |
| Nov-16-16 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-05-16 | Reiterated | Needham | Buy |
| Sep-16-16 | Initiated | H.C. Wainwright | Buy |
| Mar-30-15 | Initiated | Needham | Buy |
| Mar-30-15 | Initiated | Oppenheimer | Outperform |
View All
Summit Therapeutics Inc Stock (SMMT) Latest News
Trading Systems Reacting to (SMMT) Volatility - news.stocktradersdaily.com
Citi Asserts Buy Rating on Summit Therapeutics Inc. (SMMT) on Pipeline Development - Yahoo Finance
Citi asserts buy rating on Summit Therapeutics Inc. (SMMT) on pipeline development - MSN
Has Summit Therapeutics Rally Left Enough Upside After 448.6% Surge and DCF Upswing? - Yahoo Finance
2 Stocks Up Over 600% in the Past 3 Years With More Room to Run - Finviz
U.S. Markets Ended Tuesday Mixed As Galaxy Digital Led, Summit Therapeutics Lagged - Barron's
Summit Therapeutics (SMMT) Stock on December 9, 2025: Trial Optimism Collides With High Risk, High Volatility - ts2.tech
Duggan buys Summit Therapeutics (SMMT) shares worth $5.9m By Investing.com - Investing.com Nigeria
Norges Bank Invests $29.58 Million in Summit Therapeutics PLC $SMMT - MarketBeat
New York State Common Retirement Fund Buys 227,513 Shares of Summit Therapeutics PLC $SMMT - MarketBeat
Schroder Investment Management Group Sells 89,090 Shares of Summit Therapeutics PLC $SMMT - MarketBeat
State Board of Administration of Florida Retirement System Boosts Stake in Summit Therapeutics PLC $SMMT - MarketBeat
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Trading Near Its 52-Week Low, Is Summit Therapeutics a Good Stock to Buy Right Now? - Finviz
Trading Near Its 52-Week Low, Is Summit Therapeutics a Good Stock to Buy Right Now? - The Motley Fool
Why analysts upgrade Summit Therapeutics Inc. stockJuly 2025 Earnings & Weekly Chart Analysis and Guides - Newser
Summit Therapeutics Inc. (SMMT) Options Chain - Yahoo! Finance Canada
1 Reason I'll Never Sell Vertex Pharmaceuticals Stock - AOL.com
Summit Therapeutics (NASDAQ:SMMT) Trading 9.2% HigherShould You Buy? - MarketBeat
Can Summit Therapeutics Inc. stock maintain operating marginsWeekly Gains Report & AI Powered Market Trend Analysis - Newser
Summit Therapeutics Earnings Notes - Trefis
Don't Buy Summit Therapeutics Until This Big Thing Happen - Nasdaq
Widening Q3 Losses and Insider Buying Might Change The Case For Investing In Summit Therapeutics (SMMT) - Yahoo Finance
Summit Therapeutics (SMMT): Valuation Check After Weak Q3 2025 Results and Insider Share Purchases - Yahoo Finance
How Summit Therapeutics Inc. (SMMT) Affects Rotational Strategy Timing - news.stocktradersdaily.com
SMMT: Four positive phase 3 trials and accelerated timelines position the pipeline for NSCLC market leadership - TradingView
XTX Topco Ltd Makes New $925,000 Investment in Summit Therapeutics PLC $SMMT - MarketBeat
2 Monster Stocks in the Making to Buy and Hold - The Globe and Mail
Summit Therapeutics: InvestingPro’s Fair Value model predicted 37% downside By Investing.com - Investing.com Nigeria
Summit Therapeutics (SMMT) Stock Analysis Report | Financials & Insights - Benzinga
33,096 Shares in Summit Therapeutics PLC $SMMT Acquired by Inceptionr LLC - MarketBeat
Rhenman & Partners Asset Management AB Makes New Investment in Summit Therapeutics PLC $SMMT - MarketBeat
Summit Therapeutics PLC (NASDAQ:SMMT) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
WE Convention 2025: Dr. Maky Zanganeh, Co-CEO and President, Summit Therapeutics - Entrepreneur
January 2026 Options Now Available For Summit Therapeutics (SMMT) - Nasdaq
Summit Therapeutics Inc. (SMMT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Cynosure Group LLC Buys Shares of 18,609 Summit Therapeutics PLC $SMMT - MarketBeat
Biotech Alert: Searches spiking for these stocks today - TipRanks
40,169 Shares in Summit Therapeutics PLC $SMMT Acquired by Neo Ivy Capital Management - MarketBeat
(SMMT) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
Summit C-Suite Risks Success, Akeso Wins Either Way (OTCMKTS:AKESF) - Seeking Alpha
Jefferies Cuts Summit Therapeutics (SMMT) Price Target, Keeps Buy Rating - MSN
ProShare Advisors LLC Sells 25,455 Shares of Summit Therapeutics PLC $SMMT - MarketBeat
Is Summit Therapeutics Inc. building a consolidation baseMarket Rally & Weekly Top Stock Performers List - newser.com
What MACD and RSI say about Summit Therapeutics Inc.Gap Up & Weekly Chart Analysis and Trade Guides - newser.com
Summit: A Cautious Bet Backed By Anti-VEGF & Insider Buying (NASDAQ:SMMT) - Seeking Alpha
Has Summit Therapeutics Inc. found a price floorJuly 2025 Trends & Free Weekly Chart Analysis and Trade Guides - newser.com
Wolfe Research Initiates Coverage of Summit Therapeutics (SMMT) with Peer Perform Recommendation - Nasdaq
Summit Therapeutics at Jefferies London: Strategic Progress in Cancer Trials By Investing.com - Investing.com Canada
Wolfe Research Initiates Coverage on SMMT with 'Peer Perform' Ra - GuruFocus
Transcript : Summit Therapeutics Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-18-2025 03 - MarketScreener
Summit Therapeutics Inc Stock (SMMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Summit Therapeutics Inc Stock (SMMT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
May 30 '25 |
Option Exercise |
2.64 |
74,545 |
196,799 |
555,754,696 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
May 30 '25 |
Option Exercise |
2.64 |
74,545 |
196,799 |
555,754,696 |
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):